GenSight keeps falling after lead product underwhelms

French gene therapy company GenSight Biologics (Euronext: SIGHT) was 32% down on its value at the end of last week by Wednesday lunchtime, the firm having reported results on its lead product.

Monday was the first scheduled readout, at Week 48, of the RESCUE Phase III trial of a single intravitreal injection of GS010 in 39 subjects whose visual loss due to 11778-ND4 leber hereditary optic neuropathy (LHON) occurred up to six months prior to study treatment.

The primary efficacy endpoint, defined as a +15-letter difference in visual acuity improvement for GS010-treated eyes compared to sham-treated eyes at 48 weeks, was not met.